Pharmacy Question for the Week of August 14, 2017

Pharmacy Compliance Question of the Week


Is it true that CMS will cut reimbursement for the 340B program in 2018?


In the 2018 proposed rule for the Hospital Outpatient Prospective Payment System (OPPS), the Centers for Medicare & Medicaid Services addressed recent trends of increasing drug prices, for which some of the cost burden falls to Medicare beneficiaries. For 2018, CMS has proposed paying separately payable, non-pass-through drugs (other than vaccines) purchased at a discount through the 340B drug pricing program at an average sales price (ASP) minus 22.5 percent rather than ASP plus 6 percent. Applicable drugs not purchased under the 340B drug program would continue to receive ASP plus 6 percent payment.

Disclaimer: Every reasonable effort was made to ensure the accuracy of this information at the time it was published. However, due to the nature of industry changes over time we cannot guarantee its validity after the year it was published.